Merck licenses a KRAS G12D inhibitor for $400M upfront - endpoints.news

Source: endpoints.news · 2026-09-28T14:00:00+00:00

Merck licenses a KRAS G12D inhibitor for $400M upfront endpoints.newsMerck licenses SciBrunch cancer drug in deal worth up to $2.13 billion ReutersMerck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D Fierce BiotechMerck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor Business WireMerck inks up to…

BestAIBroker analysis

Finance-aware sentiment: positive (+0.40 on a -1 to +1 scale).
Event classification: OTHER.
Market importance score: 23/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.
Symbols referenced: ON, CDTX, ACRV, CORT, CCCC.

Read the original source